A Randomized, Controlled Trial of Daclizumab vs Anti-thymocyte Globulin Induction for Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 26, Issue 5, 2007, Pages 504-510

  Mullen, John C ^a   Oreopoulos, Antigone ^a   Lien, Dale C ^a   Bentley, Michael J ^a   Modry, Dennis L ^a   Stewart, Ken ^a   Winton, Timothy L ^a   Jackson, Kathy ^a   Doucette, Karen ^a   Preiksaitis, Jutta ^a   Halloran, Phil F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HOSPITAL COST; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 34247162655     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.01.032     Document Type: Article

References (20)

1. Hertz M., Taylor D.O., Trulick E.P., et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report-2002. J Heart Lung Transplant 21 (2002) 950-970
2. Daoud J., McCabe M., Montoya A., and Garrity E.R. The Loyola University lung transplant experience. Arch Intern Med 153 (1993) 2769
3. Cooper J., Patterson G.A., and Trulock E.P. Results of single and bilateral lung transplantation in 131 consecutive patients. J Thorac Cardiovasc Surg 107 (1994) 460
4. Moffatt S., Demers P., Robbins R.C., et al. Lung transplantation: a decade of experience. J Heart Lung Transplant 24 (2005) 145-151
5. Abramowicz D., Wissing D.M., and Broeders N. Induction therapy with anti-CD3 antibodies. Curr Opin Organ Transplant 4 (1999) 312-317
6. Zenapax product monograph (1998), Roche Pharmaceuticals, F. Hoffmann-La Roche, Ltd, Basel, Switzerland
7. Billingham M., Cary N.R.B., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Lung Transplant 6 (1990) 587-593
8. Cooper J., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature for clinical staging of chronic dysfunction in lung allografts: International Society for Heart and Lung Transplantation. J Heart Lung Transplant 12 (1993) 773-777
9. Hamilton A., Norris C., Wensel R., and Koshal A. Cost reduction in cardiac surgery. Can J Cardiol 10 (1994) 721-727
10. Sarris G., Moore K.A., Schroeder J.S., et al. Cardiac transplantation: the Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg 108 (1994) 240-252
11. Brock M., Borja M.C., Ferber L., et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 20 (2001)
12. Bhorade S., Jordan A., Villanueva J., et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant 3 (2003) 1570-1575
13. Garrity E., Villanueva J., Bhorade S.M., Husain A.N., and Vigneswaran W.T. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 71 (2001) 773-777
14. Weill D., Lock B.J., Wewers D.L., et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 3 (2003) 492-496
15. Burton C., Andersen C.B., Jensen A.S., et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 25 (2006) 638-647
16. Duncan S., Paradis I.L., Yousem S.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am J Respir Dis 146 (1992) 1419-1425
17. Singh N., Arnow P.M., Bonham A., et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 64 (1997) 716-720
18. Snydman D. Infection in solid organ transplantation. Transplant Infect Dis 1 (1999) 21-28
19. Savo A., Book B.K., Henson J., Hakimi J., and Pescovitz M.D. Daclizumab rapidly saturates interleukin-2 receptor-alpha (DC25) on lymph node lymphocytes in children. Transplant Proc 31 (1999) 1182
20. Vincenti F., Nashan B., and Light S. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 67 (1998) 110-114